Edwards Wildman Palmer LLP

Blogs

RSS

Keyword

Contact

John Tuerck
Director of Communications
617.239.0283

Industries: Life Sciences

June 14, 2013	Edwards Wildman's Ralph Loren Analyzes Myriad Decision in Law360
June 2013	Edwards Wildman Client Advisory: Supreme Court Invalidates Claims to Isolated DNA, but Upholds Patent Eligibility of cDNA in Myriad
June 4, 2013	Edwards Wildman's Ralph Loren Analyzes Shire Settlement with Teva over ADHD Drug in Life Sciences Intellectual Property Review
May 22, 2013	Edwards Wildman's Tom Wintner Co-Authors Article on the Global Biosimilars Market in Chemistry Today
May 14, 2013	Edwards Wildman's Ralph Loren and Brian Murphy Weigh In On Supreme Court's Monsanto Ruling in Law360
May 13, 2013	Edwards Wildman’s Jonathan Cole Appointed to Board of the Florida Research Consortium, Reports the South Florida Business Journal
May 13, 2013	Edwards Wildman’s Jonathan Cole Appointed to the Board of Directors of the Florida Research Consortium
May 2, 2013	Edwards Wildman's Pete Corless Analyzes Generic Drug Case in Life Sciences Intellectual Property Review
April 25, 2013	Edwards Wildman's Trio Writes Article on How Generic Drug Companies Have Seized on Inter Partes Review Proceedings in Law360
April 25, 2013	Edwards Wildman's Nat Gardiner and Stacie Aarestad Advise Enanta in IPO, Reports The American Lawyer
April 23, 2013	Edwards Wildman’s Daniel Clarke Joins Firm’s Intellectual Property Practice, Reports Boston Media
April 3, 2013	Edwards Wildman’s John Igoe Appointed to the Board of Directors of BioFlorida, Reports Florida Media
April 3, 2013	Edwards Wildman's John Igoe Appointed to the Board of Directors of BioFlorida
April 2, 2013	Edwards Wildman’s Brian Gaff Analyzes Federal Circuit Ruling on Massachusetts General Patent Dispute in the National Law Journal
March 29, 2013	Edwards Wildman’s Brian Gaff Comments on Fed. Circ. Ruling on MGH Patents in Law360
March 28, 2013	IP Team Prevails in Federal Circuit for Massachusetts General Hospital
March 15, 2013	Edwards Wildman’s Ralph Loren Examines Patent Interferences in Bloomberg BNA Patent, Trademark & Copyright Journal
February 2013	Edwards Wildman Client Advisory - Report on Hong Kong Patent System Reform
February 5, 2013	Edwards Wildman Closes Stemline Therapeutics IPO in First Biotech IPO of 2013
February 2013	UK - Key Developments in IP 2013
January 22, 2013	Edwards Wildman Trio Provides Tips on Protecting Bioinformatics as Intellectual Property in Computer Magazine Article and Podcast
November 2012	Edwards Wildman Client Advisory - English court has jurisdiction to hear pan-European declarations of non-infringement
October 2012	Edwards Wildman Client Advisory - Protected Concerted Activity: The New Frontier in the NLRB’s Increasing Focus on Non-Unionized Employers
October 2012	Edwards Wildman Client Advisory - Attention Pharmaceutical and Medical Device Executives – Ignorance is not bliss
September 2012	Edwards Wildman Attorneys co-author Article on Biosimilar challenges in Contract Pharma
September 4, 2012	Edwards Wildman: Direct Infringement by Single Entity Not Necessary for Induced Infringement of Method Patent The U.S. Court of Appeals for the Federal Circuit closes induced infringement loophole, holding there can be liability for inducement when no one entity performs all the steps of a method claim.
August 17, 2012	Edwards Wildman: MYRIAD II - Isolated DNA Claims Upheld
July 2012	Edwards Wildman Client Advisory: Court of Justice holds that prohibited distribution of copyright-protected works is not protected by free movement of goods principle Titus Alexander Jochen Donner, Case C-5/11 of 21 June 2012
July 2012	Edwards Wildman Client Advisory: Recent Developments in Wage and Hour Law
June 2012	Edwards Wildman Client Advisory: Supreme Court Rejects Department of Labor’s Definition of “Outside Salesman:” Drug Reps Lose FLSA Case Demanding Overtime Pay
June 2012	Edwards Wildman Client Advisory - Employers Need to Review and Revise Social Media, Blogging and Privacy Policies after NLRB General Counsel Report
April 26, 2012	Nick Bolter Appointed Partner-in-Charge of Edwards Wildman’s London Office
April 2012	Edwards Wildman Congressional Update - Supreme Court on Health Reform and Patent case / Budget / Transportation Programs/ FCC Reform / Cybersecurity
March 2012	Edwards Wildman Client Advisory - Citing Dukes, Louisiana High Court Halts Another Mass Tort Class Action
March 22, 2012	Edwards Wildman Named to BTI's Client Service A-Team for 2012
March 2012	Edwards Wildman Congressional Update - Latest News from Capitol Hill March 19, 2012
January 2012	Edwards Wildman Client Advisory - Acolyte Decision Shines A BacLite On Earn-out Clauses
December 2011	Client Advisory - European Commission Kicks Off Technology Transfer Block Exemption Consultation Process
December 2011	Congressional Update - Legislative Wrap Up 2011
September 2011	Congressional Update - Fall Preview
September 2011	Client Advisory - Additional Massachusetts Life Sciences Tax Incentives Authorized by 2012 State Budget Bill
August 2011	Client Advisory - Federal Circuit Upholds Patentability of Isolated DNA, but Affirms Invalidity of Claims to Methods “Comparing” or “Analyzing” Genetic Sequences
2011	Life Sciences Brochure
May 2011	Client Advisory - FDA Issues Guidance for Final Rule on the Submission of Summary Bioequivalence Data for ANDAs
January 21, 2011	John Lo and Ken Choy Join Edwards Wildman as Partners New Hong Kong Partners to Boost Firm’s Core Strengths in Business Law and IP
January 19, 2011	Thomas Wintner Selected to Participate in Boston Future Leaders Class of 2011
January 10, 2011	Niall McAlister Joins London Office of EAPD New partner augments life sciences capability in Firm’s growing office in the UK
November 2010	Client Advisory - FDA Hears Testimony on Approval Pathway for Biosimilar and Interchangeable Follow-On Biologics
November 1, 2010	Ben Goodger Joins Edwards Angell Palmer & Dodge as an Intellectual Property Partner in London
October 18, 2010	Kathy Williams Breaks Down the Biosimilars Act in the Boston Business Journal
October 14, 2010	Understand the Intricacies of Generic Biologic Drugs Boston Business Journal
September 23, 2010	Edwards Angell Palmer & Dodge Secures Top-Tier Rankings in US News and World Report’s Inaugural Survey of the Best Law Firms
2010/2011	Pharmaceutical Trademarks – A Global Guide - UK Chapter
August 2010	Client Advisory - Bilski's Impact on Biotechnology and Medical Diagnostic Claims
May 2010	Client Advisory - Therapeutic Discovery Project Tax Credit and Cash Grants of up to $5 million - Application Procedures Released in IRS Notice 2010-45
May 6, 2010	EAPD Client Wins Entrepreneur Track Category At the Rhode Island Business Plan Competition
March 2010	Client Advisory - New Law! The Biologics Price Competition and Innovation Act of 2009
February 2010	Client Advisory - Changes to Divisional Application Practice Before the European Patent Office Enter Into Force on 1 April 2010
February 2010	Client Advisory - Introduction of Further Procedural Changes at the European Patent Office from 1 April 2010
February 1, 2010	EAPD Launches "HIT" Program EAPD is “Helping Innovators Thrive” by Providing Strategic Legal Advice For New Ventures
January 2010	Client Advisory - Federal Circuit Upholds Decision Granting Additional Patent Term Adjustment to Compensate for Examination Delays
June 2009	Deadline Approaches for Compliance with Massachusetts Pharmaceutical and Medical Device Manufacturer Conduct Regulations Edwards Angell Palmer & Dodge LLP
June 2009	Client Advisory - The Follow-on Biologics Debate and the June 2009 FTC Report on Follow-on Biologic Drug Competition
March 2009	Client Advisory - The Patent Reform Act of 2009
March 2009	Client Advisory - U.S. Supreme Court Issues Decision in Wyeth v. Levine Rejecting FDA Labeling Pre-emption Argument
March 2009	Client Advisory - UK House of Lords clarifies enablement law
February 12, 2009	New Federal Red Flag, Massachusetts and Other State Data Security Rules
February 2009	Client Advisory - Don't Let Your Antitrust Guard Down: Non-Reportable Transactions May Be Scrutinized
Winter 2009	The Validity of Gene Sequence Patents in the UK
February 1, 2009	Court Ruling May Impact Life Science Patents Genetic Engineering & Biotechnology News
January 2009	Client Advisory - Siemens Case Highlights FCPA Risk In International Healthcare Industry
December 2008	Client Advisory - Enlarged Board of Appeal at the European Patent Office rejects the WARF/Thomson stem cell patent application appeal
December 2008	Client Advisory - Patentable Subject Matter: In re Bilski
October 2008	Client Advisory - Recent Massachusetts Legislation Provides $250 Million in Tax Incentives for Certified Life Sciences Companies
Autumn 2008	The Biosimilars Debate
Autumn 2008	Intellectual Property Bulletin - Autumn 2008
October 7, 2008	Dr. Tony Maschio joins Edwards Angell Palmer & Dodge as Partner in Firm's Life Science's Practice
May 14, 2008	Edwards Angell Palmer & Dodge Launches UK Patent Practice Life Sciences Partner Joins to Grow UK IP Practice
April 11, 2008	"The Times They Are A- Changin . . ." Florida's Future As A Life Science Center South Florida Business Journal
February 2008	Use and transfer of medical and clinical data in Greece Word Protection Report
September 1, 2007	Is Biomass the New Texas Tea? Solid Waste Demands Consideration as a Cheaper Source of Fuel Ethano Genetic Engineering & Biotechnology News
July/August 2007	Life cycle management of ageing pharmaceutical assets Phamaceutical Law Insight
March 26, 2007	Virtual company making $875M pharma purchase existed only on paper Daily Business Review
March 1, 2007	Licensees May Be Gaining a New Legal Weapon Supreme Court Holding in MedImmune v. Genentech Makes Licensors More Vulnerable GEN - Genetic Engineering & biotechnology News
November 1, 2006	The rise of new trends in collaborative research www.ipworldonline.com
August 1, 2006	The Pharma Name Game Trademark World
July 1, 2006	Trendspotting: betting strong but playing safe Nature Biotechnology - Volume 24, Number 7
June 1, 2006	Trendspotting: A shift in intellectual property focus Nature Biotechnology, Volume 24, Number 6
June 1, 2006	Anti-Kickback Laws Pose Risk to Health Care Deals Venture Capital Journal, Issue 6
May 1, 2006	Duty of care in Hatch-Waxman paragraph IV certifications Phamaceutical Law Insight
April 2006	Grace periods and patentability Nature Reviews Drug Discovery
December 2005	Medical treatment inventions Nature Reviews Drug Discovery
2005	How Should Inventors be Compensated for Their Contributions to U.S. Patents?
August 4, 2005	Drugs Spill Over Borders
July 14, 2005	Federal Anti-Kickback Law Applied to Medical Device and Biotech Companies
July 2005	Added matter and patentability Nature Reviews Drug Discovery
June 16, 2005	Authorized Generics: To Switch Rather than Fight!
May 8, 2005	Can A Strong Patent Position Be Illegal?
May 5, 2005	Clash of the Titans: Federal Regulations in Conflict via Drug Re-Importation
April 2005	Experimental use provision Nature Reviews Drug Discovery
February 14, 2005	Building a Cross-continental Biotech
February 4, 2005	Registration of Clinical Trials: A Bandwagon in the Making
January 2005	Experimental support and patentability Nature Reviews Drug Discovery
November 17, 2004	Maintaining the Privilege of Patent Opinions in Alliances, Mergers and Acquisisitons
November 4, 2004	Preserving the Privilege of Patent Opinions in Business Transactions
September 2004	Inventive step and genomics Nature Reviews Drug Discovery
June 18, 2004	Nanomedicine: At the intersection of nanotechnology and medical devices
June 18, 2004	As Biotechnology IPOs Go, So Goes Venture Capital
June 2, 2004	Changes in the U.S. Patent System?
May 3, 2004	SEC and FDA Increase Scrutiny of Disclosures by Biotechnology Companies
February 20, 2004	Beware Entangled Patent Laws
January 15, 2004	Competitive Pathways for FDA Approval of Generic Compounds Evolution of Section 505(b)(2) of the Federal Food Drug and Cosmetic Act
November 25, 2003	Is Biotech Manufacturing a Cure for the Economy?
November 14, 2003	Will RNAi Silence Antisense?
November 6, 2003	Off Label Marketing: New Pitfalls The Neurotonin Case
November 6, 2003	Drug Screening and Patent Infringement
September 17, 2003	You Can't Always Get What You Want in Technology Agreements
June 25, 2003	Does Drug Screening Fall Under the FDA Safe Harbor
May 9, 2003	New 'Creative' Partnership Could Improve Detection, Treatment of Cancer
April 18, 2003	The State of the Art at the U.S. Patent and Trandemark Office
April 2, 2003	Permitted Experimental Use of Patented Inventions in the European Union
February 7, 2003	Sublicense Rights - A Key Issue in Technology Licensing
January 29, 2003	Legal Uses of a Patented Invention in the U.S..: Do Your Company's Activities Fall Under the Legal Exceptions to Patent Infringement- Part II
November 5, 2002	New Biotech Business Models Need New IP Strategies
June 19, 2002	The Supreme Court Unanimously Agrees that the Doctrine of Equivalents is Alive and Well
April 26, 2002	Intellectual Property: Due Diligence
April 19, 2002	As the stent market heats up, so does litigation
March 11, 2002	Thinking Broadly in Drug Discovery
March 5, 2002	"Provisional" Patent Rights Permit Damages on a Published Patent Application!
February 20, 2002	Biotech faces 'march-in' threat
January 10, 2002	What a Biotech Up-Start Should Know About a Successful Patent Strategy: The Sword and the Shield
January 10, 2002	hat a Biotech Up-Start Should Know About A Successful Patent Strategy: The Sword and The Shield
December 6, 2001	Outsourcing Pharma Sales Creates Both Risks, Profits
November 7, 2001	Inventorship vs. Authorship
January 16, 2001	U.S. Patent Law Changes Take Effect
December 21, 2000	Advice of Counsel, November 2000
July 24, 2000	Genome success means difficult patent questions
February 14, 2000	Market is hot for biotech
January 14, 2000	Resolutions for a biotech New Year

Boston - Chicago - Hartford - Hong Kong - London - Los Angeles - Madison NJ - Miami - New York - Orange County - Providence - Stamford - Tokyo - Washington DC - West Palm Beach